-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 SW41ALC/uuhSIm4N5+GJtt06xGBoTr7Xdpoe4ZhvGQknhmf+7qIogLx9CAiTOQHv
 jhBpwiFJEJd+NZbIabE+ZA==

<SEC-DOCUMENT>0001102624-07-000038.txt : 20070207
<SEC-HEADER>0001102624-07-000038.hdr.sgml : 20070207
<ACCEPTANCE-DATETIME>20070207104449
ACCESSION NUMBER:		0001102624-07-000038
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070207
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070207
DATE AS OF CHANGE:		20070207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		07586554

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucellcorp8k.htm
<DESCRIPTION>IMMUCELL 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: February  07, 2007</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive, Portland, Maine</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>(207) 878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On February 7, 2007 ImmuCell Corporation (the "Company") issued a press release announcing its financial results for the three and twelve month periods ended December 31, 2006.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.  The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act ("the Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<br><b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated February  07, 2007</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table>
<tr>
<td width="50%" valign=top>
Dated: February  07, 2007<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated February  07, 2007</td>
</tr>
</table>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for Fourth Quarter and Full Year 2006</b>
<p>PORTLAND, ME -- 02/07/2007 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and twelve month
periods ended December 31, 2006.
</p>
<p>
For the three months ended December 31, 2006, product sales were $1,060,000
representing a decrease of $114,000, or 10%, in comparison to the same
period in 2005.  For the year ended December 31, 2006, product sales
increased by 2%, or $73,000, to $4,306,000, in comparison to the same
period in 2005.
</p>
<p>
"The annual growth in product sales is attributable principally to a 6%
increase in sales of our lead product, First Defense&#174;," commented Michael
F. Brigham, president and CEO.  "Sales of our second leading product, Wipe
Out&#174; Dairy Wipes, increased by 9%, while sales of our other minor
products declined by $157,000 as a group.  This was our eighth consecutive
profitable year since our 1999 decision to focus our business strategy on
products that improve animal health and productivity in the dairy and beef
industries."
</p>
<p>
Net income per diluted share was $0.05 and $0.21 during the three and
twelve month periods ended December 31, 2006, respectively.  The Company
recognized net income of $155,000 for the three months ended December 31,
2006, compared to net income of $260,000 during the same period in 2005.
For the twelve months ended December 31, 2006, the Company recognized net
income of $647,000, compared to net income of  $708,000 during the same
period in 2005.
</p>
<p>
"Our lead new product opportunity, Mast Out&#174; (a Nisin-based mastitis
treatment for cows), is being developed under an exclusive, worldwide
license with Pfizer Animal Health," commented Dr. Joseph H. Crabb, vice
president and chief scientific officer.  "During 2006, Pfizer made
significant progress in the areas of effectiveness, manufacturing and
pharmacokinetics and is proceeding with further development of the
product."
</p>
<p>
The Company's cash, cash equivalents and short-term investments increased
by 28%, or $1,464,000, to $6,614,000 at December 31, 2006, as compared to
$5,150,000 at December 31, 2005.  As of December 31, 2006, we had invested
approximately $300,000 in equipment and facility improvements related to
our effort to gain compliance with current Good Manufacturing Practices
(cGMP) regulations in our manufacturing operations.  We expect to invest
the remaining $1,200,000 budget for this project as the work is completed
in the first half of 2007.  Stockholders' equity increased by 9%, or
$775,000, to $9,332,000 at December 31, 2006, as compared to $8,558,000 at
December 31, 2005.  The Company had 2,896,000 shares of common stock
outstanding as of December 31, 2006.
<pre>
                                        (Unaudited)
                                    Three Months Ended  Twelve Months Ended
                                    ------------------- -------------------
                                       December 31,        December 31,
                                    ------------------- -------------------
(In thousands, except per share        2006      2005      2006      2005
 amounts)                           --------- --------- --------- ---------
Revenues:
Product sales                       $   1,060 $   1,174 $   4,306 $   4,233
Other revenues                            163       194       495       750
                                    --------- --------- --------- ---------
Total revenues                          1,223     1,368     4,801     4,983

Cost and expenses:
Product costs                             521       456     1,882     1,634
Product development expenses              264       345       966     1,270
Selling, general and administrative
 expenses                                 310       289     1,182     1,141
                                    --------- --------- --------- ---------
Total costs and expenses                1,095     1,090     4,030     4,045
                                    --------- --------- --------- ---------

Net operating income                      128       278       771       938

Interest and other income                  74        39       263       133
                                    --------- --------- --------- ---------

Income before income taxes                202       317     1,034     1,071
Income tax expense                         47        57       387       363
                                    --------- --------- --------- ---------
Net income                          $     155 $     260 $     647 $     708
                                    ========= ========= ========= =========

Net income per common share:
Basic                               $    0.05 $    0.09 $    0.22 $    0.25
Diluted                             $    0.05 $    0.09 $    0.21 $    0.24

Weighted average common shares
 outstanding:
Basic                                   2,897     2,848     2,888     2,824
Diluted                                 3,061     3,040     3,051     3,003




                                                  At December  At December
                                                    31, 2005     31, 2006
                                                  ------------ ------------
(In thousands)
Cash, cash equivalents and short-term investments $      5,150 $      6,614
Total assets                                             9,955       11,364
Net working capital                                      6,091        6,934
Stockholders&#146; equity                              $      8,558 $      9,332
</pre>
ImmuCell Corporation is a biotechnology company that is developing,
manufacturing and selling products that improve animal health and
productivity in the dairy and beef industries.  Press releases and other
information about the Company are available at http://www.immucell.com.

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
